Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Current Deferred Revenue (2016 - 2025)

Firefly Neuroscience has reported Current Deferred Revenue over the past 15 years, most recently at $249000.0 for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $249000.0 for Q4 2025, up 1815.38% from a year ago — trailing twelve months through Dec 2025 was $249000.0 (up 1815.38% YoY), and the annual figure for FY2025 was $249000.0, up 1815.38%.
  • Current Deferred Revenue for Q4 2025 was $249000.0 at Firefly Neuroscience, up from $238000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for AIFF hit a ceiling of $455496.0 in Q1 2021 and a floor of $13000.0 in Q4 2024.
  • Median Current Deferred Revenue over the past 5 years was $138391.5 (2022), compared with a mean of $156149.5.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 80.27% in 2021 and later surged 1815.38% in 2025.
  • Firefly Neuroscience's Current Deferred Revenue stood at $186835.0 in 2021, then fell by 2.18% to $182756.0 in 2022, then tumbled by 85.76% to $26026.0 in 2023, then crashed by 50.05% to $13000.0 in 2024, then surged by 1815.38% to $249000.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $249000.0 (Q4 2025), $238000.0 (Q3 2025), and $326000.0 (Q2 2025) per Business Quant data.